Appendix

Clinical Trials

Lilly & Company H8A-MC-LZAX: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo (Shankle)


TauRx TRx-237-015: Randomized, Double-Blind, PlaceboControlled, Parallel-Group, 12-Month Trial of Leucomethylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer’s Disease October 2013-(Shankle)


TauRx TRx-237-007 - A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) (Shankle)


Avid Radiopharmaceuticals, Inc 18F-AV-1451-A05 An Open Label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’s disease (Shankle)


TRx-237-020: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia (Shankle)


Biogen 221AD302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease - (Shankle)


Avid F18-AV1451-A16: A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology (Shankle)


F. Hoffman-La Roche Protocol BN29552: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMALTO-MILD ALZHEIMER’S DISEASE (Shankle)


American College of Radiology: Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study (Shankle)


SOCRATES: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin (ASA) in Patients with Acute Ischaemic Stroke or TIA (D5134C00001) 2013- (Brown)


UCB Pharma Protocol No1199: An open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment at a flexible dose up to 150 mg/day in subjects aged 16 years or older suffering from epilepsy. (Muir)


Nocimed, Inc. NM002: Clinical Development and Evaluation of the Nociscan™ Diagnostic Software Suite for Post-Processing MRI and MR Spectroscopy (MRS) of Lumbar Intervertebral Discs to Diagnose Disc Pain and Degeneration (Rhee)


Pfizer B7601003: A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBOCONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE (Thakkar)